Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sperm and leukocyte telomere length are related to sperm quality parameters in healthy men from the Led-Fertyl study

  • Fernández de la Puente, María
  • Valle Hita, Cristina|||0000-0001-5423-7466
  • Salas-Huetos, Albert|||0000-0001-5914-6862
  • Martínez, María Ángeles
  • Sánchez-Resino, Elena
  • Canudas, Silvia|||0000-0002-5630-1588
  • Torres-Oteros, Daniel
  • Relat, Joana
  • Babio, Nancy|||0000-0003-3527-5277
  • Salas-Salvadó, Jordi|||0000-0003-2700-7459
Could sperm and leukocyte telomere length (TL) be associated with sperm quality parameters and reproductive health in men from the general population? A positive association between sperm and leukocyte TL with sperm concentration and total count has been demonstrated. Male factors account for almost half of cases of couple infertility, and shorter TLs have been observed in sperm from men with impaired sperm parameters. However, evidence in men from the general population is limited. A total of 200 volunteers of reproductive age were recruited between February 2021 and April 2023 to participate in the Lifestyle and Environmental Determinants of Seminogram and Other Male Fertility-Related Parameters (Led-Fertyl) cross-sectional study. TLs in sperm and leukocytes were measured using quantitative polymerase chain reaction (qPCR) in 168 and 194 participants, respectively. Sperm parameters, including concentration, total count, motility, vitality, and morphology, were analyzed using a computer-assisted sperm analysis (CASA) SCA ® system according to the World Health Organization (WHO) 2010 guidelines. Multivariable regression models were performed to assess the associations between sperm and leukocyte TL, either in tertiles or as continuous variables, and sperm quality parameters while adjusting for potential confounders. Participants in tertiles 2 (T2) and 3 (T3) of sperm TL showed a higher sperm concentration (β: 1.09; 95% CI: 0.09-2.09 and β: 2.06; 95% CI: 1.04-3.09 for T2 and T3, respectively; P -trend < 0.001), compared to those in the reference tertile (T1). Participants in the highest tertile of sperm TL showed higher total sperm count (β: 3.83; 95% CI: 2.08-5.58 for T3 vs T1; P -trend < 0.001). Participants in the top tertile of leukocyte TL showed higher sperm concentration (β: 1.49; 95% CI: 0.44-2.54 for T3 vs T1; P -trend = 0.004), and total count (β: 3.49; 95% CI: 1.62-5.35 for T3 vs T1; P -trend < 0.001) compared with participants in T1. These results remained consistent when sperm and leukocyte TL were modelled as continuous variables. One limitation is the impossibility of establishing a cause-effect relationship due to the cross-sectional study design. Additionally, the sample size of the study cannot be considered large. Sperm and leukocyte TLs are associated with sperm quality parameters in the general population. Additional determinations and further studies with larger sample sizes are needed to clarify the mechanisms underlying these associations and to investigate the further implications. The Led-Fertyl study was supported by the Spanish government's official funding agency for biomedical research, Instituto de Salud Carlos III (ISCIII), through the Fondo de Investigación para la Salud (FIS) and co-funded by the European Union ERDF/ESF, 'A way to make Europe'/'Investing in your future' (PI21/01447), and the Diputació de Tarragona (2021/11-No.Exp. 8004330008-2021-0022642). J.S.-S., senior author of the present study, is partially supported by ICREA under the ICREA Academia program. M.F.d.l.P. was supported by a predoctoral grant from the Rovira i Virgili University and Diputació de Tarragona (2020-PMF-PIPF-8). C.V.-H. received a predoctoral grant from the Generalitat de Catalunya (2022 FI_B100108). M.Á.M. was supported by the Sara Borrell postdoctoral fellowship (CD21/00045-Instituto de Salud Carlos III (ISCIII)). All authors declare that they have no conflicts of interest. N/A.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The prognostic impact of SIGLEC5-induced impairment of CD8 + T cell activation in sepsis

  • Lozano-Rodríguez, Roberto
  • Avendaño-Ortíz, José
  • Montalbán-Hernández, Karla
  • Ruiz-Rodriguez, Juan Carlos|||0000-0001-7392-8617
  • Ferrer, Ricard|||0000-0002-4859-4747
  • Martín-Quirós, Alejandro
  • Maroun-Eid, Charbel
  • González-López, Juanjo|||0000-0003-2419-5909
  • Fàbrega-Santamaria, Anna|||0000-0002-3866-2291
  • Terrón-Arcos, Verónica
  • Gutiérrez-Fernández, María
  • Alonso-López, Elisa
  • Cubillos-Zapata, Carolina
  • Fernández Velasco, María|||0000-0002-3293-3046
  • Perez de Diego, Rebeca|||0000-0001-8426-8765
  • Pelegrín, Pablo|||0000-0002-9688-1804
  • García-Palenciano, Carlos
  • Cueto, Francisco J.
  • del Fresno, Carlos
  • López-Collazo, Eduardo
Sepsis is associated with T-cell exhaustion, which significantly reduces patient outcomes. Therefore, targeting of immune checkpoints (ICs) is deemed necessary for effective sepsis management. Here, we evaluated the role of SIGLEC5 as an IC ligand and explored its potential as a biomarker for sepsis. In vitro and in vivo assays were conducted to both analyse SIGLEC5's role as an IC ligand, as well as assess its impact on survival in sepsis. A multicentre prospective cohort study was conducted to evaluate the plasmatic soluble SIGLEC5 (sSIGLEC5) as a mortality predictor in the first 60 days after admission in sepsis patients. Recruitment included sepsis patients (n = 346), controls with systemic inflammatory response syndrome (n = 80), aneurism (n = 11), stroke (n = 16), and healthy volunteers (HVs, n = 100). SIGLEC5 expression on monocytes was increased by HIF1α and was higher in septic patients than in healthy volunteers after ex vivo LPS challenge. Furthermore, SIGLEC5-PSGL1 interaction inhibited CD8 + T-cell proliferation. Administration of sSIGLEC5r (0.8 mg/kg) had adverse effects in mouse endotoxemia models. Additionally, plasma sSIGLEC5 levels of septic patients were higher than HVs and ROC analysis revealed it as a mortality marker with an AUC of 0.713 (95% CI, 0.656-0.769; p < 0.0001). Kaplan-Meier survival curve showed a significant decrease in survival above the calculated cut-off (HR of 3.418, 95% CI, 2.380-4.907, p < 0.0001 by log-rank test) estimated by Youden Index (523.6 ng/mL). SIGLEC5 displays the hallmarks of an IC ligand, and plasma levels of sSIGLEC5 have been linked with increased mortality in septic patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Human induced pluripotent stem cell-derived myotubes to model inclusion body myositis

  • Cantó-Santos, Judith|||0000-0002-0272-7014
  • Valls-Roca, Laura|||0000-0001-5956-6752
  • Tobías, Ester|||0000-0002-9968-3651
  • García García, Francesc Josep|||0000-0001-9021-0324
  • Guitart-Mampel, Mariona
  • Andújar-Sánchez, Félix
  • Vilaseca-Capel, Adrià
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Martín-Mur, Beatriz|||0000-0002-6006-3295
  • Padrosa, Joan
  • Peruga, Emma
  • Madrigal, Irene|||0000-0002-7229-1199
  • Segalés, Paula
  • García-Ruiz, Carmen
  • Fernández-Checa, José Carlos
  • Moreno-Lozano, Pedro J.
  • Selva O'Callaghan, Albert|||0000-0003-2823-9761
  • Sevilla, Ana|||0000-0002-9251-4759
  • Milisenda, José César|||0000-0003-0151-7872
  • Garrabou, Glòria|||0000-0001-8973-9933
Inclusion body myositis (IBM) is an inflammatory myopathy that displays proximal and distal muscle weakness. At the histopathological level, the muscles of IBM patients show inflammatory infiltrates, rimmed vacuoles and mitochondrial changes. The etiology of IBM remains unknown, and there is a lack of validated disease models, biomarkers and effective treatments. To contribute to unveil disease underpins we developed a cell model based on myotubes derived from induced pluripotent stem cells (iPSC-myotubes) from IBM patients and compared the molecular phenotype vs. age and sex-paired controls (n = 3 IBM and 4 CTL). We evaluated protein histological findings and the gene expression profile by mRNA-seq, alongside functional analysis of inflammation, degeneration and mitochondrial function. Briefly, IBM iPSC-myotubes replicated relevant muscle histopathology features of IBM, including aberrant expression of HLA, TDP-43 and COX markers. mRNA seq analysis identified 1007 differentially expressed genes (DEGs) (p-value adj < 0.01; 789 upregulated and 218 downregulated), associated with myopathy, muscle structure and developmental changes. Among these, 1 DEG was related to inflammation, 28 to autophagy and 28 to mitochondria. At the functional level, inflammation was similar between the IBM and CTL groups under basal conditions (mean cytokine expression in IBM 4.6 ± 1.4 vs. 6.7 ± 3.4 in CTL), but increased in IBM iPSC-myotubes after lipopolysaccharide treatment (72.5 ± 21.8 in IBM vs. 13.0 ± 6.7 in CTL). Additionally, autophagy was disturbed, with 40.14% reduction in autophagy mediators. Mitochondrial dysfunction was strongly manifested, showing a conserved respiratory profile and antioxidant capacity, but a 56.33% lower cytochrome c oxidase/citrate synthase ratio and a 66.59% increase in lactate secretion. Overall, these findings support patient-derived iPSC-myotubes as a relevant model for IBM, reflecting the main muscle hallmarks, including inflammation, autophagy dysfunction and mitochondrial alterations at transcriptomic, protein and functional levels.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comparative mortality of dominant Staphylococcus aureus lineages in human bacteremia and animal infection models

  • Sánchez-Osuna, Miquel|||0000-0001-5267-4814
  • Bravo Bravo, Marc|||0000-0002-3173-2242
  • Cañas, María Alexandra|||0000-0002-0521-7204
  • Gómez, Andromeda-Celeste|||0000-0002-0075-6903
  • Gómez-Sánchez, Inmaculada|||0000-0002-4255-0882
  • Miró, José M.|||0000-0001-8057-7755
  • Gibert, Isidre|||0000-0003-1442-2258
  • Gasch, Oriol|||0000-0001-8518-458X
  • García de la Mària, Cristina|||0000-0002-0585-9469
  • Yero, Daniel|||0000-0002-6234-4082
  • Pich, Oscar Q.|||0000-0003-3561-630X
Staphylococcus aureus is a major human pathogen responsible for severe infections, including infective endocarditis. While host factors influencing disease outcome are well characterized, lineage-specific virulence mechanisms remain poorly defined. Herein, we investigated eighty-nine bacteremic S. aureus isolates from nine globally distributed lineages using Galleria mellonella and rabbit infection models, alongside phenotypic and transcriptomic analyses. Despite marked genotypic and phenotypic heterogeneity, mortality in G. mellonella varied significantly between lineages and correlated with hemolytic activity. ST398 isolates demonstrated heightened larval virulence linked to increased α- and δ-hemolysin production, whereas CC30 strains exhibited reduced growth, biofilm formation and infectivity. The ST398 agrC mutant Sau7 displayed a distinct phenotype, with elevated biofilm production but attenuated larval virulence. However, in the rabbit endocarditis model, Sau7 exhibited mortality rates similar to other ST398 isolates and was associated with larger vegetations and higher bacterial burdens, underscoring the role of the agr system in colonization and biofilm development. Transcriptomic profiling highlighted quorum-sensing pathways and hemolysin expression as key drivers of virulence in ST398 strains. Our findings reveal clear lineage-specific differences in S. aureus pathogenicity and demonstrate that virulence is context dependent, varying across infection models. These results emphasize the importance of using complementary in vivo systems to capture the multifaceted nature of S. aureus disease potential and to better predict infection outcomes.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Assessment of barriers for people with disability to enjoy national parks

  • Aguilar-Carrasco, Maria José
  • Riutort-Mayol, Gabriel
  • Gielen, Eric|||0000-0002-4591-2914
  • Vallés-Planells, María|||0000-0002-5932-0485
  • Galiana, Francisco|||0000-0001-7897-6538
[EN] There is increasing awareness of the importance of nature-based recreation to human wellbeing. Given its significant benefits, natural-protected area management has not always provided equitable access to all potential users. Limited research till now has been focused on how the outdoor barriers impact the equal enjoyment of people with mobility/motor disabilities (PwMDs) of nature when promoting sustainable nature-based tourism. This study intends to shed light on those aspects which constrain the PwMD¿s enjoyment of the great outdoors at national parks (NPs). The study was carried out in Canada and Spain through an online survey on amenities needed and accessibility barriers for PwMDs in parks. It was analyzed through log linear models for cross-frequency tables, which allow us to estimate the associations between questions/variables and, thus, ultimately, obtain insights into how the needs of amenities and accessibility barriers can affect and limit PwMDs¿ enjoyment of natural parks. The results show a predisposition on the part of participants to enjoy parks more frequently than they usually do, as well as a preference for forests and mountain landscapes. Information and communication technologies are the tools most chosen to prepare for their trip and visit to the park. PwMD finds barriers in NPs as impediments to benefit from nature-based recreation and adding to their wellbeing. NP managers should take into consideration that PwMD¿s visits to parks are related to the main obstacles they perceive such as slopes and pavement and that they require amenities such as recreation and signposting. They would also like to enjoy parks more often, with footpaths suitable for walkability/wheelability, e.g., compact pavement, low inclines, and adequate signposting. In addition to the physical barriers, managers should also consider intrapersonal and interpersonal constraints to provide outdoor activities in parks focused on PwMDs¿ needs., This research received partial support and external funding from the Instituto de Salud Carlos III, Spain (grant CD21/00186-Sara Borrell Postdoctoral Fellowship) and was co-funded by the European Union.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

A blood microRNA classifier for the prediction of ICU mortality in COVID-19 patients: a multicenter validation study

  • de Gonzalo Calvo, David
  • Molinero, Marta
  • Benítez, Iván D.
  • Perez Pons, Manel
  • García Mateo, Nadia
  • Ortega, Alicia
  • Postigo, Tamara
  • García Hidalgo, María C.
  • Belmonte, Thalía
  • Rodríguez Muñoz, Carlos
  • González, Jessica
  • Torres, Gerard
  • Gort Paniello, Clara
  • Moncusí Moix, Anna
  • Estella García, Ángel
  • Tamayo Lomas, Luis
  • Martínez de la Gándara, Amalia
  • Socias, Lorenzo
  • Peñasco, Yhivian
  • de la Torre, María del Carmen
  • Bustamante Munguira, Elena
  • Gallego Curto, Elena
  • Martínez Varela, Ignacio
  • Martín Delgado, María Cruz
  • Vidal Cortés, Pablo
  • López Messa, Juan
  • Pérez García, Felipe
  • Caballero, Jesús
  • Añón, José Manuel
  • Loza Vázquez, Ana
  • Carbonell, Nieves
  • Marin Corral, Judith
  • Jorge García, Ruth Noemí
  • Barberà, Carmen
  • Ceccato, Adrián
  • Fernández Barat, Laia
  • Ferrer, Ricard
  • García Gasulla, Dario
  • Lorente Balanza, Jose Ángel
  • Menéndez, Rosario
  • Motos, Ana
  • Peñuelas, Oscar
  • Riera, Jordi
  • Bermejo Martin, Jesús F.
  • Torres, Antoni
  • Barbé, Ferrán
Background: The identification of critically ill COVID-19 patients at risk of fatal outcomes remains a challenge. Here, we first validated candidate microRNAs (miRNAs) as biomarkers for clinical decision-making in critically ill patients. Second, we constructed a blood miRNA classifier for the early prediction of adverse outcomes in the ICU. Methods: This was a multicenter, observational and retrospective/prospective study including 503 critically ill patients admitted to the ICU from 19 hospitals. qPCR assays were performed in plasma samples collected within the first 48 h upon admission. A 16-miRNA panel was designed based on recently published data from our group. Results: Nine miRNAs were validated as biomarkers of all-cause in-ICU mortality in the independent cohort of critically ill patients (FDR < 0.05). Cox regression analysis revealed that low expression levels of eight miRNAs were associated with a higher risk of death (HR from 1.56 to 2.61). LASSO regression for variable selection was used to construct a miRNA classifier. A 4-blood miRNA signature composed of miR-16-5p, miR-192-5p, miR-323a-3p and miR-451a predicts the risk of all-cause in-ICU mortality (HR 2.5). Kaplan‒Meier analysis confirmed these findings. The miRNA signature provides a significant increase in the prognostic capacity of conventional scores, APACHE-II (C-index 0.71, DeLong test p-value 0.055) and SOFA (C-index 0.67, DeLong test p-value 0.001), and a risk model based on clinical predictors (C-index 0.74, DeLong test-p-value 0.035). For 28-day and 90-day mortality, the classifier also improved the prognostic value of APACHE-II, SOFA and the clinical model. The association between the classifier and mortality persisted even after multivariable adjustment. The functional analysis reported biological pathways involved in SARS-CoV infection and inflammatory, fibrotic and transcriptional pathways. Conclusions: A blood miRNA classifier improves the early prediction of fatal outcomes in critically ill COVID-19 patients., 11 páginas
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Metabolomic and Machine Learning Enhances Patient Diagnosis and Stratification in Systemic Autoimmune Diseases

  • Perez-Sanchez, Carlos
  • Perez-Campoamor, Antonio
  • Bolón-Canedo, Verónica
[Abstract]: Systemic Autoimmune Diseases (SADs) present clinical challenges due to their heterogeneity, which complicates patient classification, and delays diagnosis. We characterized their metabolomic fingerprints aiming to uncover novel molecular insights and enhance patient stratification and diagnosis through the application of Machine Learning (ML). A total of 716 individuals from the international multicenter study PRECISESADS were included: 272 with Rheumatoid Arthritis (RA), 183 with Systemic Lupus Erythematosus (SLE), 148 with Antiphospholipid Syndrome (APS), 70 with Systemic Sclerosis (SSc), and 43 Healthy Donors (HDs). The circulating metabolomic profile was analyzed using Nuclear Magnetic Resonance (NMR) spectroscopy and a combination of supervised and unsupervised ML methods. Several metabolites were differentially expressed in each disease compared to HDs, with the highest number of alterations observed in SSc (99) and APS (68), followed by SLE (30) and RA (17). The prominent reduction of antioxidant and anti-inflammatory metabolites (albumin and histidine), combined with the increase in the pro-inflammatory marker GlycA, emerged as key shared hallmarks of SADs. Each disease also displayed a distinct set of uniquely altered metabolites. ML demonstrated strong diagnostic potential (AUC 0.79–0.87) by generating disease-specific signatures driven by alterations in lipids, fatty acids, energy metabolism, and amino acid pathways. Unsupervised clustering analysis of the entire cohort identified three distinct clusters, with each disease represented across all clusters in varying proportions, which were strongly associated with distinct key clinical features. This study highlights the utility of metabolomics and ML to classify and stratify patients with SADs, reinforcing their clinical relevance in precision medicine., Supported by CPS: RYC2021-033828-I; PID2022-141500OA-I00; FAR-2024-001 scleromic; and CLP: (PI21/00591, PI21/00959, CD21/00187 and RICOR-21/0002/0033), co-financed by European Union. EU/EFPIA-IMI-PRECISESADS (n° 115565). A.P.C. was supported by STARTQUAKE S.L. and the Spanish Ministry of Science and Innovation cofunding NextGenerationEU (grant number DIN2020-011530). ALU was supported by the Spanish Ministry of Science and Innovation cofunding NextGenerationEU (grant number DIN2022-012766)., España. IMIBIC; FAR-2024-001 scleromic
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Injectable Carrageenan/Green Graphene Oxide Hydrogel: A Comprehensive Analysis of Mechanical, Rheological, and Biocompatibility Properties

  • Moncada-Villalobos, Danny
  • Bouza, Rebeca
  • Rico, Maite
  • Rodríguez-Llamazares, Saddys
  • Pettinelli, Natalia
  • Aragón Herrera, Alana
  • Feijóo-Bandín, Sandra
  • Gualillo, Oreste
  • Lago, Francisca
  • Farrag, Yousof
  • Salavagione, Horacio
[Abstract] In this work, physically crosslinked injectable hydrogels based on carrageenan, locust bean gum, and gelatin, and mechanically nano-reinforced with green graphene oxide (GO), were developed to address the challenge of finding materials with a good balance between injectability and mechanical properties. The effect of GO content on the rheological and mechanical properties, injectability, swelling behavior, and biocompatibility of the nanocomposite hydrogels was studied. The hydrogels’ morphology, assessed by FE-SEM, showed a homogeneous porous architecture separated by thin walls for all the GO loadings investigated. The rheology measurements evidence that G′ > G″ over the whole frequency range, indicating the dominant elastic nature of the hydrogels and the difference between G′ over G″ depends on the GO content. The GO incorporation into the biopolymer network enhanced the mechanical properties (ca. 20%) without appreciable change in the injectability of the nanocomposite hydrogels, demonstrating the success of the approach described in this work. In addition, the injectable hydrogels with GO loadings ≤0.05% w/v exhibit negligible toxicity for 3T3-L1 fibroblasts. However, it is noted that loadings over 0.25% w/v may affect the cell proliferation rate. Therefore, the nano-reinforced injectable hybrid hydrogels reported here, developed with a fully sustainable approach, have a promising future as potential materials for use in tissue repair., The research was funded by Xunta de Galicia Government: program of consolidation and structuring competitive research units [Grant number: ED431C 2019/17]. The work of Centro de Investigación de Polímeros Avanzados, CIPA is funded by ANID Regional [R23F0005] and the work of N.P is funded by ANID Fondecyt Postdoctoral [3230505]. Y.F is a ‘Sara Borrell’ researcher funded by the Instituto de Salud Carlos III (ISCIII) and co-funded by Fondo Europeo de Desarrollo Regional (FEDER) [CD21/00042]. The work of O.G. (PI20/00902) is funded by ISCIII, FEDER, and Xunta de Galicia, Consellería de Educación, Universidade e Formación Profesional and Consellería de Economía, Emprego e Industria (GAIN) (GPC IN607B2022/03). H.J.S is grateful for the funding from the Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación (AEI), grant PID2020-117573GB-I00., Xunta de Galicia; ED431C2019/17, Xunta de Galicia; IN607B2022/03, Chile. Agencia Nacional de Investigación y Desarrollo; R23F0005, Chile. Agencia Nacional de Investigación y Desarrollo; 3230505
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

Dietary antioxidant intake reduces carotid intima-media thickness in coronary heart disease patients: From the CORDIOPREV study

  • Rivas García, Lorenzo
  • Quintana-Navarro, Gracia M.
  • Torres‑Peña, J.D.
  • Arenas de Larriva, Antonio P.
  • Alcalá Díaz, Juan Francisco
  • Yubero-Serrano, Elena M.
  • Pérez-Caballero, Ana I.
  • Ortiz Morales, Ana María
  • Rangel Zúñiga, Oriol Alberto
  • López-Moreno, Alejandro
  • Ordovás, José María
  • Pérez-Martínez, Pablo
  • López-Miranda, José
  • Delgado-Lista, Javier
Background: Atherosclerosis is the leading underlying cause of coronary heart disease (CHD). In patients with CHD, intima-media thickness of common carotid arteries (IMT-CC) is a reliable, validated, and non-invasive marker of the progression of atherosclerosis. Dietary intervention may affect IMT-CC evolution through different pathways. There is a lack of clinical trials evaluating the effect of total dietary antioxidant content of diets on IMT-CC, especially in patients with CHD. Objective: We evaluated the correlation between the diet's total antioxidant content and the changes in IMT-CC produced after 5 years of dietary intervention following two healthy diet models (Mediterranean diet and low-fat diet). We also evaluated whether the diet's total antioxidant content was related to the total redox capacity of the participants. Methods: From the total participants of the CORDIOPREV study (clinical trial register NCT00924937), 805 participants completed the IMT-CC measurement and the dietary antioxidant evaluation at baseline and after 5 years of dietary intervention. IMT-CC was carried out by ultrasound and the dietary antioxidant evaluation was performed by the Dietary Antioxidant Index (DAI). Additionally, direct redox balance was evaluated in a subset of population by the ratio of reduced glutathione (GSH) to oxidized glutathione (GSSH) by colorimetric assay. Results We observed an inverse correlation between evolution of DAI and IMT-CC after 5-years of dietary intervention. The mean of the DAI index augmented in the Mediterranean Diet group, whereas it decreased in the Low-fat group. DAI was correlated to the GSH/GSSG ratio, supporting DAI as an adequate estimator of diet's antioxidant content. When looking for individual components of the DAI that were associated to the changes in IMT-CC, an inverse correlation was found for carotenoids, vitamin E, vitamin C, and zinc and the IMT-CC. Conclusions: Our study indicates that, after five years of dietary intervention, changes in DAI inversely correlate with changes in IMT-CC in patients with CHD. Overall effect of Mediterranean diet resulted in an increase of DAI, conversely to low-fat. Specific elements included in the DAI index were inversely correlated with IMT-CC.
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

Metabolomic and machine learning enhances patient diagnosis and stratification in systemic autoimmune diseases

  • Pérez-Sánchez, Carlos
  • Perez-Campoamor, Antonio
  • García-Delgado, Gema Dolores
  • Vellón-García, Beatriz
  • Llamas Urbano, Adrián
  • Romero-Zurita, Laura
  • Ortiz-Buitrago, Pedro
  • Merlo, Christian
  • Cerdó, Tomás
  • Corrales, Sagrario
  • Sanchez-Pareja, Ismael
  • Muñoz-Barrera, Laura
  • Ábalos-Aguilera, María del Carmen
  • Barbarroja, Nuria
  • Bolón-Canedo, Verónica
  • Ortega-Castro, Rafaela
  • Calvo, Jerusalem
  • Ladehesa-Pineda, Lourdes
  • Aranda-Valera, I. Concepción
  • Beretta, Lorenzo
  • Vigone, Barbara
  • Pers, Jacques‐Olivier
  • Saraux, Alain
  • Devauchelle-Pensec, Valérie
  • Cornec, Divi
  • Jousse‐Joulin, Sandrine
  • Lauwerys, Bernard
  • Ducreux, Julie
  • Maudoux, Anne‐Lise
  • Vasconcelos, Carlos
  • Tavares, Ana
  • Neves, Esmeralda
  • Faria, Raquel
  • Brandão, Mariana
  • Campar, Ana
  • Marinho, António
  • Farinha, Fátima
  • Almeida, Isabel
  • Gonzalez‐Gay Mantecón, Miguel Angel
  • Blanco Alonso, Ricardo
  • Corrales Martínez, Alfonso
  • Cervera, Ricard
  • Rodríguez-Pintó, Ignasi
  • Espinosa, Gerard
  • Lories, Rik
  • De Langhe, Ellen
  • Hunzelmann, Nicolas
  • Belz, Doreen
  • Witte, Torsten
  • Baerlecken, Niklas
  • Stummvoll, Georg
  • Zauner, Michael
  • Lehner, Michaela
  • Collantes Estévez, Eduardo
  • Ortega-Castro, Rafaela
  • Aguirre‐Zamorano, Ma Angeles
  • Escudero-Contreras, Alejandro
  • Castro-Villegas, M. Carmen
  • Ortego-Centeno, Norberto
  • Fernández Roldán, María Concepción
  • Raya, Enrique
  • Jiménez Moleón, Inmaculada
  • De Ramón, Enrique
  • Díaz Quintero, Isabel
  • Meroni, Pier Luigi
  • Gerosa, Maria
  • Schioppo, Tommaso
  • Artusi, Carolina
  • Chizzolini, Carlo
  • Zuber, Aleksandra
  • Wynar, Donatienne
  • Kovács, László
  • Balog, Attila
  • Deák, Magdolna
  • Bocskai, Márta
  • Dulic, Sonja
  • Kádár, Gabriella
  • Hiepe, Falk
  • Gerl, Velia
  • Thiel, Silvia
  • Rodriguez Maresca, Manuel
  • López‐Berrio, Antonio
  • Aguilar‐Quesada, Rocío
  • Navarro‐Linares, Héctor
  • Alarcon-Riquelme, Marta
  • Aguirre, María Ángeles
  • Escudero-Contreras, Alejandro
  • López-Pedrera, Chary
Systemic Autoimmune Diseases (SADs) present clinical challenges due to their heterogeneity, which complicates patient classification, and delays diagnosis. We characterized their metabolomic fingerprints aiming to uncover novel molecular insights and enhance patient stratification and diagnosis through the application of Machine Learning (ML). A total of 716 individuals from the international multicenter study PRECISESADS were included: 272 with Rheumatoid Arthritis (RA), 183 with Systemic Lupus Erythematosus (SLE), 148 with Antiphospholipid Syndrome (APS), 70 with Systemic Sclerosis (SSc), and 43 Healthy Donors (HDs). The circulating metabolomic profile was analyzed using Nuclear Magnetic Resonance (NMR) spectroscopy and a combination of supervised and unsupervised ML methods. Several metabolites were differentially expressed in each disease compared to HDs, with the highest number of alterations observed in SSc (99) and APS (68), followed by SLE (30) and RA (17). The prominent reduction of antioxidant and anti-inflammatory metabolites (albumin and histidine), combined with the increase in the pro-inflammatory marker GlycA, emerged as key shared hallmarks of SADs. Each disease also displayed a distinct set of uniquely altered metabolites. ML demonstrated strong diagnostic potential (AUC 0.79–0.87) by generating disease-specific signatures driven by alterations in lipids, fatty acids, energy metabolism, and amino acid pathways. Unsupervised clustering analysis of the entire cohort identified three distinct clusters, with each disease represented across all clusters in varying proportions, which were strongly associated with distinct key clinical features. This study highlights the utility of metabolomics and ML to classify and stratify patients with SADs, reinforcing their clinical relevance in precision medicine.
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

Unveiling Endotypes in Systemic Lupus Erythematosus Through Multiomic Analysis: Insights Into Cardiovascular and Renal Complications

  • Cerdó, Tomás
  • Woodridge, Laurel
  • Corrales, Sagrario
  • Muñoz-Castañeda, Juan R.
  • Torralbo, Ana Isabel
  • Rahman, Anisur
  • Farinha, Filipa
  • Ortega-Castro, Rafaela
  • Segui, Pedro
  • Sánchez-Pareja, Ismael
  • Muñoz-Barrera, Laura
  • Merlo, Christian
  • Ruiz-Vilchez, Desirée
  • Ábalos-Aguilera, María del Carmen
  • Font-Ugalde, Pilar
  • Barbarroja, Nuria
  • PRECISESADS Clinical Consortium
  • Alarcón-Riquelme, Marta
  • Escudero-Contreras, Alejandro
  • Aguirre-Zamorano, M. Ángeles
  • Pérez-Sánchez, Carlos
  • Jury, Elizabeth C.
  • López-Pedrera, Chary
Objective: Systemic lupus erythematosus (SLE) shows clinical and molecular heterogeneity, and cardiovascular (CV) complications and lupus nephritis (LN) remain leading causes of morbidity and mortality. This study investigated whether omic profiling can reveal molecular endotypes linked to these outcomes. Methods: Serum from 199 patients with SLE underwent proximity extension assay–based proteomics and targeted nuclear magnetic resonance metabolomics. Unsupervised clustering was performed on proteomic data, followed by integrative multiomic factor analysis, logistic regression, and machine learning models. Cohorts with SLE from the University College London, a subset with expanded Olink Reveal panel and untargeted metabolomics, and in vitro (human umbilical vein endothelial cell and HK2) and ex vivo (rat kidneys) models exposed to patient sera were used for validation and mechanistic exploration. Results: Proteomic clustering identified two molecular subgroups (cluster 1 and cluster 2). Compared with cluster 2, cluster 1 showed damage burden and increased rates of LN (1.8-fold), hypertension (3-fold), dyslipidemia (2-fold), obesity (8-fold), and abnormal C-reactive protein/erythrocyte sedimentation rate (4-fold), consistent with CV risk. A total of 47 inflammatory and organ-damage proteins and multiple metabolites were increased in cluster 1. Neural network models based on metabolites and clinical variables discriminated clusters (area under the curve = 0.77), highlighting citrate and lipoproteins as key features. Multiomic analyses and external cohorts confirmed reproducibility and enrichment in pathways related to leukocyte trafficking, endothelial stress, and nephritis. In vitro, serum from patients with SLE induced NF-κB activation in rat kidneys compared with controls, supporting a proinflammatory effect. Conclusion: Multiomic profiling delineates molecular endotypes in SLE, integrating immune, vascular, and metabolic pathways associated with CV risk and LN, supporting their potential for precision risk stratification.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Evaluating the Immunological Impact of Hepatitis B Vaccination in Patients with Inflammatory Bowel Disease

  • Soledo, Irene
  • Marín C, Alicia
  • Baldan-Martin, Montse
  • Bernardo, David
  • Chaparro, María
  • Gisbert, Javier P
Patients with inflammatory bowel disease (IBD) frequently fail to achieve protective immunity after hepatitis B vaccination, even with intensified vaccination schedules. In this observational real-world study, 18 patients with IBD who were seronegative for hepatitis B virus (HBV) received three standard doses of the Engerix-B® vaccine (at 0, 1, and 6 months). After immunisation, patients were classified into responders and non-responders according to their serological response. Blood samples were collected before the first dose and after completion of the vaccination schedule. Responders activated pathways that supported durable protection, including conventional dendritic cells type 1 mobilisation, expansion of IgG plasmablasts, and preservation of B- and T-cell memory. In contrast, non-responders displayed a more inflammatory innate profile, characterised by enrichment of CCR2+ monocytes. They also showed higher baseline Treg frequencies, which may suppress effective effector responses, together with impaired natural killer (NK) activation and progressive loss of memory potential. This study shows that hepatitis B vaccine failure in inflammatory bowel disease reflects a convergence of excessive immune regulation, inflammatory activation, and loss of memory potential, underscoring that no single pathway can explain the impaired response, Funding: This study was funded through the Instituto de Salud Carlos III (Sara Borrell fellowships; CD21/00014), Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Anticoagulant Treatment in Severe ARDS COVID-19 Patients

  • Ceccato, Adrian|||0000-0001-9454-062X
  • Camprubí-Rimblas, Marta|||0000-0002-4085-5324
  • Campaña-Duel, Elena|||0000-0002-0658-6255
  • Areny-Balagueró, Aina|||0000-0001-9611-1781
  • Morales-Quinteros, Luis|||0000-0002-8937-9824
  • Artigas Raventós, Antoni|||0000-0002-8029-1017
Patients with COVID-19 may complicate their evolution with thromboembolic events. Incidence of thromboembolic complications are high and also, patients with the critically-ill disease showed evidence of microthrombi and microangiopathy in the lung probably due to endothelial damage by directly and indirectly injured endothelial and epithelial cells. Pulmonary embolism, deep venous thrombosis and arterial embolism were reported in patients with COVID-19, and several analytical abnormal coagulation parameters have been described as well. D-dimer, longer coagulation times and lower platelet counts have been associated with poor outcomes. The use of anticoagulation or high doses of prophylactic heparin is controversial. Despite the use of anticoagulation or high prophylactic dose of heparin have been associated with better outcomes in observational studies, only in patients with non-critically ill disease benefits for anticoagulation was observed. In critically-ill patient, anticoagulation was not associated with better outcomes. Other measures such as antiplatelet therapy, fibrinolytic therapy or nebulized anticoagulants are being studied in ongoing clinical trials.
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Longitudinal recovery trajectories and ventilatory modalities in COVID-19 acute respiratory distress syndrome survivors

  • González, Jessica
  • Benítez, Iván D.
  • Santisteve, Sally
  • Vila, Anna
  • Aguilà, Maria
  • Torres, Gerard
  • Sánchez Cucó, Anna
  • Malla Bañeres, Mar
  • Moncusí Moix, Anna
  • Batlle, Jordi de
  • Gracia Lavedan, Esther
  • Ceccato, Adrián
  • Ferrer, Ricard
  • Motos, Anna
  • Riera, Jordi
  • Fernández, Laia
  • Menéndez, Rosario
  • Lorente, José Ángel
  • Peñuelas, Oscar
  • García, Darío
  • Roca, Oriol
  • Peñasco, Yhivian
  • Ricart, Pilar
  • Martín Delgado, María Cruz
  • Aguilera, Luciano
  • Rodriguez, Alejandro
  • Boado Varela, María Victoria
  • Pérez García, Felipe|||0000-0002-4885-4334
  • Pozo Laderas, Juan Carlos
  • Solé Violan, Jordi
  • Adell Serrano, Berta
  • Andrea Novo, Mariana
  • Barberán, José
  • Amaya Villar, Rosario
  • Gonzalo Calvo, David de
  • Torres, Antoni
  • Barbé, Ferran
  • Roche Campo, Ferrán
CIBERESUCICOVID Group: José Garnacho-Montero, Jose M. Gómez, Aaron Blandino Ortiz, Luis Tamayo Lomas, Alejandro Úbeda, Mercedes Catalán-González, Angel Sánchez-Miralles, Ignacio Martinez Varela, Ruth Noemí Jorge García, Nieves Franco, Victor D. Gumucio-Sanguino, Elena Bustamante-Munguira, Luis Jorge Valdivia, Jesús Caballero, Elena Gallego, Amalia Martínez de la Gándara, Alvaro Castellanos-Ortega, Josep Trenado, Judith Marin-Corral, Guillermo M. Albaiceta, Maria del Carmen de la Torre, Ana Loza-Vázquez, Pablo Vidal, Jose M. Añón, Cristina Carbajales Pérez, Victor Sagredo, Nieves Carbonell, Lorenzo Socias, Carme Barberà, Angel Estella, Emili Diaz, Fatty Seck, Adriano D.S. Targa, Inmaculada Salvador-Adell, Luis Urrelo-Cerrón, Mireia Serra-Fortuny and Esther Sauras-Colón., Background The impact of different ventilatory support modalities and timing of intubation on longitudinal lung recovery trajectories in patients with severe coronavirus disease 2019 (COVID-19) is unknown. Methods This was a multicentre, prospective observational study conducted in 52 Spanish intensive care units (ICUs) involving critically ill COVID-19 patients admitted between 25 February 2020 and 8 February 2021. 1854 COVID-19 patients were followed after hospital discharge at 3, 6 and 12 months with diffusing capacity of the lung for carbon monoxide (DLCO) measurements and chest imaging. Patients were classified regarding the ventilatory support received during the ICU stay: noninvasive mechanical ventilation (NIMV), high-flow nasal cannula (HFNC) and invasive mechanical ventilation (IMV), divided into early IMV (intubation within 24 h) and late IMV (intubation after 24 h). The primary objective was to evaluate the impact of the different respiratory support modalities during the ICU stay and the time of intubation on DLCO measurements and their recovery trajectories over a 1-year follow-up. Secondary outcomes included other pulmonary function parameters and chest imaging findings. Results A total of 360 (19.4%) and 290 (15.6%) patients received HFNC and NIMV, respectively. 1204 (64.9%) patients underwent IMV; 966 received early IMV and 238 received late IMV. The latter exhibited a significantly worse percentage predicted DLCO during the 1-year follow-up with adjusted differences of 6.9 (95% CI 3.9-10; p<0.001), 4.2 (95% CI 1.1-7.2; p=0.007) and 4.9 (95% CI 1.7-8.2; p=0.003) at 3, 6 and 12 months compared with early IMV. NIMV patients exhibited greater lung damage at follow-up than those under HFNC with an adjusted difference of percentage predicted DLCO of 5.2 (95% CI 1.7-8.7; p=0.003) at 6 months and greater presence of radiological abnormalities during follow-up. Matched and sensitivity analysis showed results consistent with those reported. Conclusions Delay in intubation implies the worst outcomes; however, patients with NIMV exhibited a slower lung recovery in terms of DLCO measurements and more radiological abnormalities compared with HFNC patients. These results should be used to optimise follow-up protocols for COVID-19 acute respiratory distress syndrome (ARDS) survivors., Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional, Fondo Social Europeo Plus, Centro de Investigación Biomédica en Red, Fundación Francisco Soria Melguizo
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Immunosuppressed patients with COVID-19 pneumonia in ICU: clinical characteristics and factors influencing outcomes

  • Galli, Flavia
  • Forin, Edoardo
  • Motos, Ana
  • Molina Saldarriaga, Francisco José
  • Gabarrús, Albert
  • Canseco, Joan
  • Fernández Barat, Laia
  • Barbeta, Enric
  • Calabretta, Davide
  • Ceccato, Adrián
  • Bermejo Martín, Jesús Francisco
  • Ferrer, Ricard
  • Riera, Jordi
  • Peñuelas, Oscar
  • Lorente, José Ángel
  • Gonzalo Calvo, David de
  • Menéndez, Rosario
  • González, Jessica
  • Palomeque, Andrea
  • Soler Comas, Alba
  • Amaya Villar, Rosario
  • Anon, José Manuel
  • Balan Mariño, Ana
  • Barberà, Carme
  • Barberán, José
  • Blandino Ortiz, Aaron Rolando
  • Bustamante Munguira, Elena
  • Caballero, Jesús
  • Cantón Bulnes, María Luisa
  • Carbajales Pérez, Cristina
  • Carbonell, Nieves
  • Catalán González, Mercedes
  • Frutos, Raúl de
  • Franco, Nieves
  • Galbán, Cristóbal
  • López Lago, Ana
  • Gumucio Sanguino, Víctor D.
  • Torre, María del Carmen de la
  • Díaz, Emilio
  • Estella, Ángel
  • Gallego Curto, Elena
  • García Garmendia, José Luis
  • Gómez, José Manuel
  • Huerta, Arturo
  • Jorge García, Ruth Noemí
  • Loza Vázquez, Ana
  • Marín Corral, Judith
  • Martín Delgado, María Cruz
  • Martínez de la Gándara, Amalia
  • Martínez Varela, Ignacio
  • López Messa, Juan
  • Albaiceta, Guillermo M.
  • Andrea Novo, Mariana
  • Peñasco, Yhivian
  • Pérez García, Felipe|||0000-0002-4885-4334
  • Pozo Laderas, Juan Carlos
  • Ricart, Pilar
  • Sagredo, Víctor
  • Sánchez Miralles, Ángel
  • Sancho Chinesta, Susana
  • Roche Campo, Ferran
  • Socias Crespí, Lorenzo
  • Solé Violan, Jordi
  • Suarez Sipmann, Fernando
  • Tamayo Lomas, Luis
  • Trenado, José
  • Úbeda, Alejandro
  • Valdivia, Luis Jorge
  • Vidal, Pablo
  • Boado, María Victoria
  • Rodriguez, Alejandro
  • Ferrer, Miquel
  • Barbé, Ferran
  • Torres, Antoni
  • CIBERESUCICOVID Project investigators
CIBERESUCICOVID Project investigators (COV20/00110, ISCIII): Rafael Mañez, Felipe Rodríguez de Castro, María Mora Aznar, Mateu Torres, María Martinez, Cynthia Alegre, Sofía Contreras, Javier Trujillano, Montse Vallverdú, Miguel León, Mariona Badía, Begoña Balsera, Lluís Servià, Judit Vilanova, Silvia Rodríguez, Neus Montserrat, Silvia Iglesias, Javier Prados, Sula Carvalho, Mar Miralbés, Josman Monclou, Gabriel Jiménez, Jordi Codina, Estela Val, Pablo Pagliarani, Jorge Rubio, Dulce Morales, Andrés Pujol, Àngels Furro, Beatriz García, Gerard Torres, Javier Vengoechea, Silvia Gomez, Lorena Forcelledo Espina, Emilio García Prieto, Paula Martín Vicente, Cecilia Del Busto Martínez, María Aguilar Cabello, Carmen Eulalia Martínez Fernández, María Luisa Blasco Cortés, Ainhoa Serrano Lázaro, Mar Juan Díaz, María Teresa Bouza Vieiro, Inés Esmorís Arijón, David Campi Hermoso, Rafaela Nogueras Salinas, Teresa Farre Monjo, Ramon Nogue Bou, Gregorio Marco Naya, Núria Ramon Coll, Juan Carlos Montejo-González, Gloria Renedo Sanchez-Giron, Juan Bustamante-Munguira, Ramon Cicuendez Avila, Nuria Mamolar Herrera, Alexander Agrifoglio, Lucia Cachafeiro, Emilio Maseda, Albert Figueras, Maria Teresa Janer, Laura Soliva, Marta Ocón, Luisa Clar, JIgnacio Ayestarán, Sandra Campos Fernández, Eva Forcadell-Ferreres, Immaculada Salvador-Adell, Neus Bofill, Berta Adell-Serrano, Josep Pedregosa Díaz, Núria Casacuberta-Barberà, Luis Urrelo-Cerrón, Àngels Piñol-Tena, Pablo Ryan Murúa, Covadonga Rodríguez Ruíz, Laura Carrión García, Juan ILazo Álvarez, Desire Macias Guerrero, Daniel Tognetti, Carlos García Redruello, David Mosquera Rodríguez, Eva María Menor Fernández, Sabela Vara Adrio, Vanesa Gómez Casal, Marta Segura Pensado, María Digna Rivas Vilas, Amaia García Sagastume, Raul de Pablo Sánchez, David Pestaña Laguna, Tommaso Bardi, Carmen Gómez Gonzalez, Maria Luisa Gascón Castillo, José Garnacho-Montero, Joan Ramon Masclans, Ana Salazar Degracia, Judit Bigas, Rosana Muñoz-Bermúdez, Clara Vilà-Vilardel, Francisco Parrilla, Irene Dot, Ana Zapatero, Yolanda Díaz, María Pilar Gracia, Purificación Pérez, Andrea Castellví, Cristina Climent, Lidia Serra, Laura Barbena, Iosune Cano, Alba Herraiz, Pilar Marcos, Laura Rodríguez, Maria Teresa Sariñena, Ana Sánchez, Juan Fernando Masa Jimenez, Gemma Gomà, Mercedes Ibarz, Diego De Mendoza, Victoria Alcaraz-Serrano, Joan Ramon Badia, Manuel Castella, Leticia Bueno, Catia Cillóniz, Pamela Conde, Javier Fernández, Karsa Kiarostami, Alexandre López-Gavín, Cecilia L Mantellini, Carla Speziale, Nil Vázquez, Hua Yang, Minlan Yang, Carlos Ferrando, Pedro Castro, Marta Arrieta, Jose Maria Nicolas, Rut Andrea, Marta Barroso, Sergio Álvarez, Dario Garcia-Gasulla, Adrián Tormos, Cesar Aldecoa, Rubén Herrán-Monge, José Ángel Berezo García, Pedro Enríquez Giraudo, Pablo Cardinal Fernández, Alberto Rubio López, Orville BáezPravia, Leire Pérez Bastida, Antonjo Alvarez Ruiz, Anna Parera Pous, Ana López Lago, Eva Saborido Paz, Patricia Barral Segade, Manuel Valledor Mendez, Luciano Aguilera, Esther López-Ramos, Ángela Leonor Ruiz-García, Belén Beteré, Rafael Blancas, Cristina Dólera, Gloria Perez Planelles, Enrique Marmol Peis, Maria Dolores Martinez Juan, Miriam Ruiz Miralles, Eva Perez Rubio, Maria Van der Hofstadt Martin-Montalvo, Tatiana Villada Warrington, Sara Guadalupe Moreno Cano, Federico Gordo, Basilisa Martinez Palacios, Maria Teresa Nieto, Sergio Ossa, Ana Ortega, Miguel Sanchez, Bitor Santacoloma, Introduction. COVID-19 severely impacted global health, especially older adults and those with comorbidities. Immunosuppressed patients are at high risk for severe outcomes, yet studies yield conflicting mortality rates for this group. This study examines the clinical characteristics and outcomes of immunosuppressed (IS) versus non-immunosuppressed (nIS) patients with COVID-19 in ICUs.MethodsA multicenter, observational case-control study included 5,824 ICU patients with COVID-19 from the CIBERESUCICOVID study. Patients were categorized as IS or nIS based on history of transplantation, HIV, active neoplasia, and use of immunosuppressive drugs or corticosteroids. The primary outcome was 90-day mortality; secondary outcomes included in-hospital, 15-day, 30-day and 1-year mortality, ICU-free days, ventilator-free days, and hospital length of stay. Subgroup analyses examined vaccination status and tocilizumab treatment. Propensity score (PS) matching was used to obtain balance among the baseline variables in the two groups.ResultsIS patients (n = 689, 11.8%) were older, had more comorbidities, and higher APACHE-II scores. After PS matching, IS patients had higher 90-day mortality (39 vs. 33%; HR 1.30, 95% CI 1.04 to 1.62), as well as higher in-hospital (37 vs. 29%; sHR 1.35, 95% CI 1.08 to 1.69), 30-day (28 vs 23%; HR 1.31, 95% CI 1.01 to 1.69) and 1-year mortality (45 vs. 38%; HR 1.26, 95% CI 1.02 to 1.57). Among IS patients, transplant recipients had significantly higher 90-day mortality after matching (HR 4.45, 95% CI 1.46 to 13.58). Vaccinated IS patients showed higher mortality than vaccinated nIS patients, though differences were not significant after PS matching. Tocilizumab treatment in IS patients was associated with reduced mortality; multivariable analysis confirmed a significant decrease in in-hospital mortality (sHR 0.56, 95% CI 0.42 to 0.76).ConclusionCritical immunosuppressed patients with COVID-19 have higher mortality, particularly transplant recipients. Tocilizumab shows potential benefits for IS patients. These findings highlight the need for tailored therapeutic strategies for immunosuppressed individuals with severe COVID-19. Further research is needed to confirm these results in the current clinical context., Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional, Centro de Investigación Biomédica en Red, Unión Española de Entidades Aseguradoras y Reaseguradoras, European Social Fund